source
- Novo’s CagriSema shows over 20% weight loss at low doses in Phase 3 trialNovo Nordisk presented new Phase 3 data on its experimental obesity combo CagriSema at ObesityWeek 2026. The low‑dose arm (1 mg and 1.7 mg weekly) achieved average weight reductions of about 21% a…
- Helus Pharma's modified psilocybin meets primary and secondary goals in phase 3 depression trialHelus Pharma reported that its oral, chemically modified psilocybin candidate, HLP003, was tested in a phase 3 study of 222 patients with major depressive disorder. Participants received a single 1…